About Court Report:  Each week we will report briefly on recently filed biotech and pharma cases.

Hetero Labs Ltd, Unit V et al. v. Pharmacia & Upjohn Co. LLC
1:15-cv-05396; filed June 18, 2015 in the Northern District of Illinois

• Plaintiffs:  Hetero Labs Ltd, Unit V; Hetero USA, Inc.
• Defendant:  Pharmacia & Upjohn Co. LLC

Declaratory judgment of non-infringement of U.S. Patent Nos. 6,514,529 ("Oxazolidinone Tablet Formulation," issued February 4, 2003) and 6,559,305 ("Linezolid – Crystal Form II," issued May 6, 2003) in conjunction with Hetero's filing of an ANDA to manufacture a generic version of Pfizer's Zyvox® (linezolid, used to treat bacterial infections).  View the complaint here.  [NB: The complaint was later voluntarily dismissed.]

Meda Pharmaceuticals Inc. v. Roxane Laboratories, Inc.
1:15-cv-00510; filed June 17, 2015 in the District Court of Delaware

Infringement of U.S. Patent Nos. 8,017,073 ("Compositions Comprising Azelastine and Methods of Use Thereof," issued December 6, 2011) and 8,518,919 (same title, issued August 27, 2013) following a Paragraph IV certification as part of Roxane's filing of an ANDA to manufacture a generic version of Meda's Astepro® (azelastine hydrochloride nasal spray, used to treat hay fever and allergy symptoms).  View the complaint here.

Par Pharmaceutical Inc. et al. v. Breckenridge Pharmaceutical Inc. et al.
1:15-cv-00486; filed June 12, 2015 in the District Court of Delaware

• Plaintiffs:  Par Pharmaceutical Inc.; Alkermes Pharma Ireland Ltd.
• Defendants:  Breckenridge Pharmaceutical Inc.; TWi Pharmaceuticals Inc.; TWi Pharmaceuticals USA Inc.

Infringement of U.S. Patent No. 9,040,088 ("Nonoparticulate Megestrol Formulations," issued May 26, 2015) in conjunction with defendants' filing of an ANDA to manufacture a generic version of Par's Megace ES® (megestrol acetate, used for the treatment of appetite loss, severe malnutrition, or unexplained, significant weight loss in AIDS patients).  View the complaint here.